Eczema treatment in South Africa has made great strides, with new therapies emerging for those with moderate to severe conditions. These treatments aim to address the underlying causes of inflammation and have significantly improved the quality of life for many patients.
However, access to these advanced options can be limited due to their high cost and availability, particularly within the public healthcare system. The development of these therapies has sparked discussions around affordability, accessibility through medical aid schemes, and their potential to revolutionise eczema care in the country.

Dr Suretha Kannenberg (Dermatologist), Dr Thulja Trikamjee (Specialist Paediatrician and Allergologist) and Kelly du Plessis (CEO & Founder of Rare Diseases South Africa).

For more information: https://www.allergyfoundation.co.za